Published online before print April 19, 2007

This Article Full Text (Rapid PDF) All Versions of this Article: ajpath.2007.061205v1 170/6/2122    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shen, X. Z. Articles by Bernstein, K. E. Search for Related Content PubMed Articles by Shen, X. Z. Articles by Bernstein, K. E.

Copyright © 2007 American Society for Investigative Pathology
American Journal of Pathology, doi:10.2353/ajpath.2007.061205

Accepted for publication February 27, 2007.

Article

Mice with Enhanced Macrophage Angiotensin-Converting Enzyme Are Resistant to Melanoma

Xiao Z. Shen^*, Ping Li^*, Daiana Weiss, Sebastien Fuchs^*, Hong D. Xiao^*, Jon A. Adams^*, Ifor R. Williams^*, Mario R. Capecchi, W. Robert Taylor, and Kenneth E. Bernstein^*@

From the Department of Pathology and Laboratory Medicine,* Emory University, Atlanta, Georgia; the Department of Medicine, Emory University, Atlanta, Georgia; and the Howard Hughes Medical Institute, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, Utah

^@ To whom correspondence should be addressed. E-mail: kbernst{at}emory.edu.

	Abstract

Angiotensin-converting enzyme (ACE) is a peptidase responsible for the cleavage of angiotensin I and several other peptides. Here, gene targeting was used to switch control of the ACE locus from the endogenous promoter to the macrophage-specific c-fms promoter. Challenge of these mice, called ACE 10/10, with the aggressive mouse melanoma cell line B16 showed that they are remarkably resistant to tumor growth. Tumor resistance was seen after challenge with different melanoma cell lines and in mice with different genetic backgrounds. Histological study of the tumors that did grow in ACE 10/10 mice showed an enhanced inflammatory response. ACE 10/10 mice had increased numbers of tumor epitope-specific CD8⁺ T cells after challenge with melanoma or lymphoma. ACE 10/10 macrophages showed increased production of interleukin-12 and nitric oxide but reduced interleukin-10. Engraftment of wild-type mice with ACE 10/10 bone marrow transferred B16 tumor resistance. Injection of B16 tumors with ACE 10/10 macrophages also reduced tumor growth. ACE 10/10 mice may define a new means of enhancing the immune response, which may be potentially useful in several human clinical situations.

This article has been cited by other articles:

				E. I. Ager, J. Neo, and C. Christophi The renin-angiotensin system and malignancy Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684. [Abstract] [Full Text] [PDF]

				X. Z. Shen, A. E. Lukacher, S. Billet, I. R. Williams, and K. E. Bernstein Expression of Angiotensin-converting Enzyme Changes Major Histocompatibility Complex Class I Peptide Presentation by Modifying C Termini of Peptide Precursors J. Biol. Chem., April 11, 2008; 283(15): 9957 - 9965. [Abstract] [Full Text] [PDF]

				L. Rush Vet. Pathol., November 1, 2007; 44(6): 965 - 965. [Full Text] [PDF]